Atopic dermatitis negatively impacts family life
A recent survey showed correlation between the severity of atopic dermatitis and the negative impacts on family life.
Atopic dermatitis in pediatric patients leads to negative effects on physical, economic, social, and emotional aspects of family life, according to a recent study.
A cross-sectional, web-based survey was administered to children and adolescents aged 6 months to under 18 years and their parents or caregivers across 18 countries encompassing North America, Latin America, Europe, Middle East/Eurasia, and East Asia. These children and adolescents had been identified with atopic dermatitis by the International Study of Asthma and Allergies in Childhood criteria.
The Patient-Oriented Eczema Measure and the Patient Global Assessmentwas used to determine the severity of each case. Finally, the impact on families’ lives was determined through the Dermatitis Family Impact questionnaire. The 7465 pairs of pediatric patients surveyed were divided into subscales based on the severity of atopic dermatitis.
Subscale scores with a greater severity of atopic dermatitis reported a greater negative impact on family life in every aspect, alongside greater sleep and tiredness. Parents missed more workdays and spent more time on childcare in more severe cases. Trends did not change between age groups.
Reference
Barbarot S, Silverberg JI, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, et al. The family impact of atopic dermatitis in the pediatric population: results from an international cross-sectional study. J Pediatr. 2022;246:220-226.e5. doi:10.1016/j.jpeds.2022.04.027
Worsening severity of AD in children associated with increased comorbidity onset risk
November 27th 2023Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort, investigators of a Sweden, nationwide, population-based cohort study found.
Lebrikizumab improves AD symptoms for adolescents inadequately controlled with cyclosporine
October 17th 2023Of the patients that responded to lebrikizumab at week 16 in the phase 3 trials ADvocate 1 and ADvocate 2, 84% achieved a clinically meaningful response in at least 1 domain of the disease (mild signs, symptoms, or quality of life impact) at 52 weeks.
Tapinarof cream 1% reduces itch as early as 24 hours after application for pediatric AD
October 13th 2023A rapid reduction in pruritis as early as 24 hours after first application was announced as new positive data from a pair of identical, phase 3 studies of tapinarof cream 1% in children as young as 2 years and adults with atopic dermatitis (AD).
Arcutis submits roflumilast 0.15% sNDA for AD in children 6 years and up
September 21st 2023Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older.
Roflumilast cream 0.05% safe, effective for children aged 2 to 5 years with atopic dermatitis
September 20th 2023Based on recent positive phase 3 results, Arcutis Biotherapeutics,. intends to submit a supplemental New Drug Application with the FDA for roflumilast cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years.
